Cantor Fitzgerald Starts Ventrus Biosciences (VTUS) at Buy; N-T Binary Play

Cantor Fitzgerald initiates coverage on Ventrus Biosciences (NASDAQ: VTUS) with a Buy. PT $29.00.

Analyst, Irina Rivkind, said, "The company is developing iferanserin, a topical ointment for the treatment of hemorrhoids, which would be a first-in-class prescription drug in an extremely large market with no meaningful competitors. The first Phase III trial reads out in June 2012; if positive, we believe it could result in a significant run-up in the stock or a potential company acquisition."

For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.

Shares of Ventrus Biosciences closed at $10.18 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Leerink Starts Ligand Pharma (LGND) at Outperform